WVE
Wave Life SciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Post-selloff valuation now leans heavily on whether Wave can re-center the story on WVE-006 and on a cleaner Phase 2 obesity setup. The best bull path is a solid ATS WVE-006 update plus successful Phase 2a initiation for WVE-007, with cash runway into 3Q 2028 buying time for both.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.0.
What can break
Biotech sentiment can stay weak even with adequate cash runway if catalysts remain early-stage and binary.
Momentum
6
Value
41
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.80 · Bull $13.50 · Bear $3.80
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $23.83
Why
Momentum6 · Δ7d +5.6
Value41 · Δ7d -0.1
Sentiment76 · Δ7d +5.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
6
26% active weight
Current posture
7d trendImproving
Δ7d
+5.6
Δ21d
+5.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
76
34% active weight
Current posture
7d trendImproving
Δ7d
+5.0
Δ21d
-0.7
Why this grade
Composite grade D. Momentum 6.3 / Value 41.1 / Sentiment 75.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.12B
Beta
-1.77
Shares Out
192.4M
P/E (TTM) · Derived
-4.8
P/S (TTM)
25.10
P/FCF (TTM) · Derived
-5.56
Rev YoY
+316.9%
EPS YoY
-54.8%
Gross Margin
+87.5%
Op Margin
-124.5%
Net Debt
-$584.3M
Current Ratio
11.26
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology